Objective: To examine ocular findings in Japanese children with nephrotic syndrome who receive prolonged corticosteroid treatment. Methods: Information was retrospectively obtained from each patient’s record. Results: A total of 45 children (30 boys and 15 girls) were enrolled. Twenty-one patients (46.7%) had epiblepharon with inverted eyelashes. The incidence of epiblepharon was associated with overweight and obesity. Fifteen patients (33.3%) developed posterior subcapsular cataract in both eyes. Of the 15 patients, 4 had visual acuity less than 0.4 and underwent cataract extraction in both eyes. Nine patients (20%) developed intraocular pressure higher than 22 mm Hg during corticosteroid treatment. The total dose and duration of corticosteroid treatment were associated with cataract formation but were unassociated with elevated intraocular pressure. One boy had elevated intraocular pressure after cessation of corticosteroid therapy and underwent trabeculectomy. One patient had repeated hordeolum in the left eyelid. Three patients had bilateral bacterial conjunctivitis. Conclusion: Children with nephrotic syndrome who receive corticosteroid treatment may have epiblepharon, cataract, ocular hypertension, hordeolum and bacterial conjunctivitis.

Keywords:
Nephrotic syndrome, Corticosteroid, Epiblepharon
1.
Friedman AL, Chesney RW: Glucocorticoids in renal disease. Am J Nephrol 1982;2:330–341.
2.
Trompeter RS: Immunosuppressive therapy in the nephrotic syndrome in children. Pediatr Nephrol 1989;3:194–200.
3.
Urban RC Jr, Cotlier E: Corticosteroid-induced cataracts. Surv Ophthalmol 1986;31:102–110.
4.
Mino M, Ueda Y, Hayashi M, Tanabe Y: Posterior subcapsular cataract in children on long term corticoid therapy. Acta Paediatr Jpn 1969;11:1–5.
5.
Kobayashi Y, Akaishi K, Nishio T, Kobayashi Y, Kimura Y, Nagata M: Posterior subcapsular cataract in nephrotic children receiving steroid therapy. Am J Dis Child 1974;128:671–673.
6.
Shiono H, Oonishi M, Yamaguchi M, Sakamoto F, Umetsu A, Kadowaki J, Ooguchi M, Oono S: Posterior subcapsular cataracts associated with long-term oral corticosteroid therapy. Clin Pediatr 1977;16:726–728.
7.
Brocklebank JT, Harcourt RB, Meadow SR: Corticosteroid-induced cataracts in idiopathic nephrotic syndrome. Arch Dis Child 1982;53:30–34.
8.
Limaye SR, Pillai S, Tina LU: Relationship of steroid dose to degree of posterior subcapsular cataracts in nephrotic syndrome. Ann Ophthalmol 1988;20:225–227.
9.
Kaye LD, Kalenak JW, Price RL, Cunningham R: Ocular implications of long-term prednisone therapy in children. J Pediatr Ophthalmol Strabismus 1993;30:142–144.
10.
Ng JSK, Wong W, Law RWK, Hui J, Wong EN, Lam DSC: Ocular complications of paediatric patients with nephrotic syndrome. Clin Exp Ophthalmol 2001;29:239–243.
11.
Hayasaka Y, Hayasaka S: Epiblepharon with inverted eyelashes and high body mass index in Japanese children. J Pediatr Ophthalmol Strabismus 2005;42:300–303.
12.
Nephrotic syndrome in children: a randomized trial comparing two prednisone regimens in steroid-responsive patients who relapse early. Report of the International Study of Kidney Disease in Children. J Pediatr 1979;95:239–243.
13.
Cole TJ, Bellizzi MC, Flegal KM, Dietz WH: Establishing a standard definition for child overweight and obesity world wide: international survey. Br Med J 2000;320:1240–1243.
14.
Chylack LT Jr, Wolfe JK, Singer DM, Leske MC, Bullimore MA, Bailey IL, Friend J, McCarthy D, Wu SY: The lens opacity classification system III. Arch Ophthalmol 1993;111:831–836.
15.
Hayasaka S, Noda S, Setogawa T: Epiblepharon with inverted eyelashes in Japanese children. II. Surgical repairs. Br J Ophthalmol 1989;73:128–130.
16.
Noda S, Hayasaka S, Setogawa T: Epiblepharon with inverted eyelashes in Japanese children. I. Incidence and symptoms. Br J Ophthalmol 1989;73:126–127.
17.
Carter SR, Seiff SR, Grant E, Vigneron DB: The Asian lower eyelid: a comparative anatomic study using high-resolution magnetic resonance imaging. Ophthalmol Plast Reconstr Surg 1998;14:227–234.
18.
Kohn R: Congenital anomalies of the eyelid and socket; in Hornblass A (ed): Orbital and Reconstructive Surgery. Baltimore, Williams & Wilkins, 1988, pp 103–118.
19.
Conlon MR, Sutula FC: Congenital eyelid anomalies; in Albert DM, Jacobiec FA (eds): Principles and Practice of Ophthalmology. Philadelphia, Saunders, 1994, pp 1693–1702.
20.
Fine RN, Offner G, Wilson WA, Mickey MR, Pennisi AJ, Malekzadeh MH: Posterior subcapsular cataracts: posttransplantation in children. Ann Surg 1975;182:585–589.
21.
Adhikary HP, Sells RA, Basu PK: Ocular complications of systemic steroid after renal transplantation and their association with HLA. Br J Ophthalmol 1982;66:290–291.
22.
Tripathi RC, Kirschner BS, Kipp M, Tripathi BJ, Slotwiner D, Borisuth NSC, Karrison T, Ernest JT: Corticosteroid treatment for inflammatory bowel disease in pediatric patients increases intraocular pressure. Gastroenterology 1992;102:1957–1961.
23.
Ohji M, Kinohita S, Ohmi E, Kuwayama Y: Marked intraocular pressure response to instillation of corticosteroids in children. Am J Ophthalmol 1991;112:450–454.
24.
Schnaper HW: The immune system in minimal change nephrotic syndrome. Pediatr Nephrol 1989;3:101–110.
25.
Iwasaki M, Kusumoto Y, Amemiya T: Uveitis in nephrotic syndrome. Metab Pediatr System Ophthalmol 1993;16:46–48.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.